Akcea and Ionis Confirm Positive Trial Results for Hypertriglyceridemia Treatment

Akcea Therapeutics (NASDAQ: AKCA) and Ionis Pharmaceuticals (NASDAQ: IONS) announced on Tuesday the results for a phase 2 trial featuring AKCEA-ANGPTL3- LRx, a drug candidate developed to combat hypertriglyceridemia. Patients with non-alcoholic fatty liver disease, type 2 diabetes, and hypertriglyceridemia (elevated triglyceride levels) showed significant improvements in their blood work.